A crosslinked polymer skin barrier film for moderate to severe atopic dermatitis: A pilot study in adults.
Occlusive treatments are a mainstay in atopic dermatitis (AD) management, but may not be well tolerated or lack compliance. A comfortable, semi-occlusive, artificial skin barrier that is well tolerated, provides protection, and reduces water loss, is desired. To evaluate, in adults with AD, the potential tolerability and therapeutic benefits of a crosslinked polymer skin barrier film (XPL). A single center, open-label pilot study was conducted involving ten subjects with moderate to severe AD. Subjects applied XPL up to twice daily for 30 days on a selected treatment area. Investigator's Global Assessment (IGA), clinical signs of eczema, and pruritus were assessed on days 1, 3, 5, 15, and 30. Film durability and subject satisfaction were also evaluated. IGA scores improved from moderate to severe at baseline to clear to almost clear in 8/9 subjects at day 30. Pruritus improved from trace-to-severe itching (baseline) to all subjects having trace-to-no itching at day 30. There was one adverse event of mild exudative dermatitis. The study was limited by small sample size, open-label design, and lack of control. XPL may be an effective adjuvant in AD treatment. A larger study with a control group is warranted.